The exact molecular functions of Polo-like kinase 1 (PLK1) in mitotic prophase are not fully understood. This study shows that PLK1 inhibition delays activation of CDK1-cyclin B and halts cells for ...

A team led by Prof. Wuran Wei from West China Hospital of Sichuan University and Dr. Dechao Feng from the Division of Surgery and Interventional Science at University College London has systematically ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

The use of AI in drug discovery and development has been recognised, explored, and implemented throughout the last decade, ...

NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for ...

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

Scientists dive into the genomes of whales, elephants, and other animal giants looking for new weapons in the fight against ...

We found that the expression levels of CDK2, Cyclin E1 (CCNE1) and Cyclin E2 (CCNE2) were decreased in BD-treated cells in a dose- and time- dependent manner (Figures 2C,D). These results suggest that ...